Harald H. Sitte

Prof. Harald H. Sitte

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2012 in Neuropsychopharmacology
Verified
Journal Article
Closed access
MBMichael Baumann
Michael Baumann
JPJohn S Partilla
John S Partilla
KLKurt R Lehner
Kurt R Lehner
ETEric B Thorndike
Eric B Thorndike
AHAlexander F Hoffman
Alexander F Hoffman
CSCharles W Schindler
Charles W Schindler

1 January 2015 in Trends in Pharmacological Sciences
Verified
Journal Article
Open access
HSHarald H. Sitte
Harald H. Sitte
MFMichael Freissmuth
Michael Freissmuth
In monoaminergic neurons, the vesicular transporters and the plasma membrane transporters operate in a relay. Amphetamine and its congeners target this relay to elicit their actions: most amphetamines are substrates, which pervert the relay to elicit efflux of monoamines into the synaptic cleft. However, some amphetamines act as transporter inhibitors. Both compound classes elicit profound psychostimulant effects, which render them liable to recreational abuse. Currently, a surge of new psychoactive substances occurs on a global scale. Chemists bypass drug bans by ingenuous structural variations, resulting in a rich pharmacology. A credible transport model must account for their distinct mode of action and link this to subtle differences in activity and undesired, potentially deleterious effects.

1 August 2006 in Neuron
Verified
Journal Article
Closed access
JFJacob U. Fog
Jacob U. Fog
Habibeh KhoshboueiHabibeh Khoshbouei
Habibeh Khoshbouei
MHMarion Holy
Marion Holy
WOWilliam A. Owens
William A. Owens
CVChristian Bjerggaard Vægter
Christian Bjerggaard Vægter
UGUlrik Gether
Ulrik Gether

1 September 1998 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
HSHarald H. Sitte
Harald H. Sitte
SHS. Huck
S. Huck
HRH. Reither
H. Reither
Stefan BoehmStefan Boehm
Stefan Boehm
ESE. A. Singer
E. A. Singer
CPChristian Pifl
Christian Pifl
Amphetamine and related substances induce dopamine release. According to a traditional explanation, this dopamine release occurs in exchange for amphetamine by means of the dopamine transporter (DAT). We tested this hypothesis in human embryonic kidney 293 cells stably transfected with the human DAT by measuring the uptake of dopamine, tyramine, and d‐ and l‐amphetamine as well as substrate‐induced release of preloaded N‐methyl‐4‐[3H]phenylpyridinium ([3H]MPP+). The uptake of substrates was sodium‐dependent and was inhibited by ouabain and cocaine, which also prevented substrate‐induced release of MPP+. Patch‐clamp recordings revealed that all four substrates elicited voltage‐dependent inward currents (on top of constitutive leak currents) that were prevented by cocaine. Whereas individual substrates had similar affinities in release, uptake, and patch‐clamp experiments, maximal effects displayed remarkable differences. Hence, maximal effects in release and current induction were ∼25% higher for d‐amphetamine as compared with the other substrates. By contrast, dopamine was the most efficacious substrate in uptake experiments, with its maximal initial uptake rate exceeding those of amphetamine and tyramine by factors of 20 and 4, respectively. Our experiments indicate a poor correlation between substrate‐induced release and the transport of substrates, whereas the ability of substrates to induce currents correlates well with their releasing action.

15 April 2008 in Neurology
Verified
Journal Article
Closed access
PDF file
ARA. H. Rajput
A. H. Rajput
HSHarald H. Sitte
Harald H. Sitte
ARA. Rajput
A. Rajput
MFM. E. Fenton
M. E. Fenton
CPChristian Pifl
Christian Pifl
OHO. Hornykiewicz
O. Hornykiewicz
Background: Patients with Parkinson disease (PD) may be akinetic/rigid, be tremor dominant, or have comparable severity of these motor symptoms (classic). The pathophysiologic basis of different PD phenotypes is unknown. This study assessed pallidal and striatal dopamine level patterns in different motor subgroups of PD and normal control brains.

1 February 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Johannes A. SchmidJohannes A. Schmid
Johannes A. Schmid
PSPetra Scholze
Petra Scholze
OKOliver Kudlacek
Oliver Kudlacek
MFMichael Freissmuth
Michael Freissmuth
ESErnst A. Singer
Ernst A. Singer
HSHarald H. Sitte
Harald H. Sitte
Recent biochemical studies indicate that the serotonin transporter can form oligomers. We investigated whether the human serotonin transporter (hSERT) can be visualized as an oligomer in the plasma membrane of intact cells. For this purpose, we generated fusion proteins of hSERT and spectral variants of the green fluorescent protein (cyan and yellow fluorescent proteins, CFP and YFP, respectively). When expressed in human embryonic kidney 293 cells, the resulting fusion proteins (CFP-hSERT and YFP-hSERT) were efficiently inserted into the plasma membrane and were functionally indistinguishable from wild-type hSERT. Oligomers were visualized by fluorescence resonance energy transfer microscopy in living cells using two complementary methods, i.e. ratio imaging and donor photobleaching. Interestingly, oligomerization was not confined to hSERT; fluorescence resonance energy transfer was also observed between CFP- and YFP-labeled rat γ-aminobutyric acid transporter. The bulk of serotonin transporters was recovered as high molecular weight complexes upon gel filtration in detergent solution. In contrast, the monomers of CFP-hSERT and YFP-hSERT were essentially undetectable. This indicates that the homo-oligomeric form is the favored state of hSERT in living cells, which is not significantly affected by coincubation with transporter substrates or blockers. Based on our observations, we conclude that constitutive oligomer formation might be a general property of Na+/Cl−-dependent neurotransmitter transporters.